DIOS 202
Alternative Names: DIOS-202Latest Information Update: 02 Aug 2021
At a glance
- Originator University of Bonn
- Developer DiosCURE Therapeutics; University of Bonn
- Class Antivirals; Immunoglobulins
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 28 Jul 2021 DiosCURE in-licenses additional intellectual property related to DIOS 203 from University of Bonn and Scripps Research Institute for COVID-2019 infections
- 12 Jan 2021 DiosCURE Therapeutics in-licenses DIOS 202 from Univeristy of Bonn for COVID-2019 infections
- 12 Jan 2021 Preclinical trials in COVID-2019 infections (Prevention) in Germany (Parenteral)